Clincosm LogoSign in Get a demo

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

Sponsor
Albert B. Sabin Vaccine Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT05343871
Collaborator
Aga Khan University (Other), Oswaldo Cruz Foundation (Other), Stanford University (Other)
2,880
Enrollment
2
Locations
21
Arms
10.9
Anticipated Duration (Months)
1440
Patients Per Site
132.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with variant-fueled case spikes causing repeated cycles of morbidity and mortality. The rapid development and emergency use authorization of vaccines against SARS-CoV-2 presents an enormous opportunity to protect populations, but bottlenecks in production have led to demand for vaccines that far outpaces supply. This project will investigate the immunogenicity of fractional doses of SARS-CoV-2 vaccines given a minimum of six months following an initial two-dose schedule or following natural immunity via documented infection. The consortium of research partners from the Sabin Vaccine Institute, Aga Khan University, Fundação Oswaldo Cruz (Fiocruz), and Stanford University will recruit volunteers to receive a full or fractional booster dose of BNT162b2, AZD1222 or Sinovac following receipt of their primary vaccination series or PCR-confirmed natural infection in Pakistan. The research team will follow participants for six months from boosting, with blood draws at baseline, 28 days, 3 months and 6 months, and measure sero-response rate (SRR) by anti-Spike immunoglobulin G (IgG) binding enzyme-linked immunosorbent assay (ELISA) with the ultimate aim of identifying whether fractional doses provide a similar immune response compared to full doses of vaccine.

Condition or Disease Intervention/Treatment Phase
  • Biological: Sinovac
  • Biological: AZD1222
  • Biological: BNT162b2
 Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2880 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The study will be observer-blind. Participants, data collectors (e.g., Investigator), and data evaluators (e.g., trial statisticians) are blinded. Only the staff involved in vaccine delivery will be unblinded and aware of which vaccine the participant is receiving (group allocation). Study staff who collect information on symptoms and adverse events, laboratory staff and statisticians conducting the analysis will all be blinded to the vaccine and dosage received.
Primary Purpose:
Prevention
Official Title:
Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy Adults
Actual Study Start Date :
Jul 5, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Priming Group 1: Sinovac Prime, AZD1222 ½ dose

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Active Comparator: Priming Group 1: Sinovac Prime, AZD1222 full dose

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Experimental: Priming Group 1: Sinovac Prime, BNT162b2 1/3 dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 1: Sinovac Prime, BNT162b2 1/2 dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Active Comparator: Priming Group 1: Sinovac Prime, BNT162b2 full dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Active Comparator: Priming Group 1: Sinovac Prime, Sinovac full dose

Biological: Sinovac
Sinovac inactivated COVID-19 vaccine: ● Full dose (0.5 ml)
Experimental: Priming Group 2: AZD1222 Prime, AZD1222 ½ dose

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Active Comparator: Priming Group 2: AZD1222 Prime, AZD1222 full dose

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Experimental: Priming Group 2: AZD1222 Prime, BNT162b2 1/3 dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 2: AZD1222 Prime, BNT162b2 1/2 dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Active Comparator: Priming Group 2: AZD1222 Prime, BNT162b2 full dose

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 3-B: BNT162b2 Prime, AZD1222 ½ dose (Brazil only)

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Active Comparator: Priming Group 3-B: BNT162b2 Prime, AZD1222 full dose (Brazil only)

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Experimental: Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/3 dose (Brazil only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/2 dose (Brazil only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Active Comparator: Priming Group 3-B: BNT162b2 Prime, BNT162b2 full dose (Brazil only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 3-P: Natural Infection Prime, AZD1222 ½ dose (Pakistan only)

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Active Comparator: Priming Group 3-P: Natural Infection Prime, AZD1222 full dose (Pakistan only)

Biological: AZD1222
AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine: Full dose (0.5 ml) Half dose (0.25 ml)
Experimental: Priming Group 3-P: Natural Infection Prime, BNT162b2 1/3 dose (Pakistan only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Experimental: Priming Group 3-P: Natural Infection Prime, BNT162b2 1/2 dose (Pakistan only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)
Active Comparator: Priming Group 3-P: Natural Infection Prime, BNT162b2 full dose (Pakistan only)

Biological: BNT162b2
Pfizer/BioNTech BNT162b2 mRNA vaccine: Full dose (30 micrograms) Half dose (15 micrograms) One-third dose (10 micrograms)

Outcome Measures

Primary Outcome Measures

  1. Sero-response rate by Spike IgG binding ELISA at 28 days post booster [Day 28]

    Assess and compare humoral immune response from a fractional vs. full booster dose of BNT162b2 or AZD1222 in immunocompetent adults fully primed with BNT162b2, AZD1222, or Sinovac vaccines or natural infection, measured by anti-Spike IgG binding ELISA at 28 days post booster

  2. Safety and reactogenicity profile of fractional and full dose of study vaccines at 28 days post-booster vaccination [Day 28]

    Describe the safety and reactogenicity profile of fractional and full dose of study vaccines at 28 days post-booster vaccination through estimated incidence of solicited local and systemic adverse events, and incidence of unsolicited reported adverse events Occurrence of solicited local and systemic reactions within 7 days of booster Occurrence of unsolicited AEs within 28 days of booster

Secondary Outcome Measures

  1. Sero-response rate by anti-Spike IgG binding ELISA at 3m and 6m post booster [Month 3 and Month 6]

    Assess the persistence of humoral immunity after a fractional vs. full booster dose of BNT162b2 or AZD1222 in immunocompetent adults fully primed with BNT162b2, AZD1222, or Sinovac vaccines or natural infection, measured by anti-Spike IgG binding ELISA at 3m and 6m post booster

  2. Safety and reactogenicity profile of fractional and full dose of study vaccines throughout the trial [Throughout study, 6 months per participant]

    Describe the safety and reactogenicity profile of fractional and full dose of study vaccines throughout the trial Occurrence of Medically attended adverse reactions within 3 months of booster Occurrence of adverse events (AE), Serious adverse events (SAE), and adverse events of special interest (AESI) within 28 days, 3 months, and 6 months of booster

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy male or female individuals aged 18 years to 60 years

  • Participant is willing and able to give written informed consent for participation in the trial

  • Individuals who can comply with trial procedures and are available for the duration of follow-up.

Brazil:

● Previous vaccination with a complete primary series of Sinovac (Priming Group 1), AZD1222 (Priming Group 2), or BNT162b2 (Priming Group 3-B) at least 6 months prior to screening

Pakistan:

● Previous vaccination with a complete primary series of Sinovac (Priming Group 1) or AZD1222 (Priming Group 2) at least 6 months prior to screening, or PCR-confirmed natural infection (Priming Group 3-P) between February 2021 - 6 months prior to screening

Exclusion Criteria:

  • Has a contraindication to BNT162b2, AZD1222 or Sinovac

  • Has received an incomplete primary COVID-19 vaccination series

  • Has received 3 doses of COVID-19 vaccine

  • Has received heterologous primary COVID-19 vaccination series

  • History of a solid organ or bone marrow transplant

  • History of malignancy (other than non-melanoma skin cancer) within the past five years

  • Currently on hemodialysis

  • Any confirmed or suspected immunosuppressive or immunodeficiency condition or diagnosis

  • On chronic (>30 days) use of immunosuppressive medications at the time of enrollment (except topical steroids or short-term oral steroids, i.e., ≤14 days)

  • Known diagnosis of HIV with CD4 count <200 cells/mm3 (in the past 6 months)

  • Active or history of previous auto-immune neurological disorders (e.g., multiple sclerosis, Guillain-Barre syndrome, transverse myelitis) (excluding Bell's palsy)

  • Has received anti-CD20 monoclonal antibodies for any reason in the past 12 months

  • Has received monoclonal antibodies to treat a previous COVID-19 event

  • Pregnant at screening

  • Positive SARS-CoV-2 Antigen test in respiratory specimen at screening

  • Planning to migrate out of the study area within 6 months of the enrollment

  • Participants currently enrolled in any other COVID-19 vaccine research trial in which they are getting a COVID-19 vaccine during the study period

  • Illiterate individuals (Brazil only)

  • Has a severe and/or uncontrolled comorbidity

Pakistan (natural infection Priming Group (Priming Group 3-P)):

● Prior vaccination with ANY vaccine against COVID-19

Contacts and Locations

Locations

Site City State Country Postal Code
1 FIOCRUZ Campo Grande MS Do Sul Brazil
2 Aga Khan University Clinical Trials Unit Karachi Sindh Pakistan

Sponsors and Collaborators

  • Albert B. Sabin Vaccine Institute
  • Aga Khan University
  • Oswaldo Cruz Foundation
  • Stanford University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Albert B. Sabin Vaccine Institute
ClinicalTrials.gov Identifier:
NCT05343871
Other Study ID Numbers:
  • Sabin CoV 22
First Posted:
Apr 25, 2022
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Albert B. Sabin Vaccine Institute
Fractional dose
COVID-19
Additional relevant MeSH terms:
COVID-19

Study Results

No Results Posted as of Jul 27, 2022